Difference between revisions of "Glycoprotein non-metastatic B"
Jump to navigation
Jump to search
(carete) |
|||
| Line 10: | Line 10: | ||
*[[Low-grade oncocytic tumour]] (LOT). | *[[Low-grade oncocytic tumour]] (LOT). | ||
*[[PEComa]]. | *[[PEComa]]. | ||
*[[RCC with | *[[RCC with fibromyomatous stroma]]. | ||
==References== | ==References== | ||
Revision as of 13:28, 26 March 2024
Glycoprotein non-metastatic B, abbreviated GPNMB, is an immunostain.
It is typically positive in TSC1/TSC2/MTOR mutated renal cell carcinomas.[1]
Positive
- Angiomyolipoma.
- TFE3-rearranged renal cell carcinoma.
- TFEB-rearranged renal cell carcinoma.
- Low-grade oncocytic tumour (LOT).
- PEComa.
- RCC with fibromyomatous stroma.
References
- ↑ Li H, Argani P, Halper-Stromberg E, Lotan TL, Merino MJ, Reuter VE, Matoso A (November 2023). "Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others". Am J Surg Pathol 47 (11): 1267–1273. doi:10.1097/PAS.0000000000002117. PMID 37661807.